

Press Release

Kraig Biocraft Laboratories, Inc. to Employ Artificial DNA Sequences for Development of New Materials for Technical Textile Market

- New Fusion Molecule Seen as Avenue for Pursuing Slice of \$127 Billion Market -

LANSING, MI - May 7, 2008 -- Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced today that the Company, working in cooperation with leading university laboratories, is synthesizing DNA sequences for artificial spider silk based polymers. The artificial DNA which the company is developing relates to the discovery of a chimera molecule, the subject of a 2008 provisional patent filing, which incorporates high strength spider silk proteins.

“Our artificial DNA sequences are designed for use in the development and production of a new class of high performance fibers,” said Kraig’s CEO Kim Thompson. “We are developing these fibers, spider silk analogs, specifically to capture a share of the growing technical fibers market. This is the primary market for high strength fibers. The market for technical fibers is booming. Within two years it is projected to grow to \$127 billion. We believe that these revolutionary materials will have tremendous potential in the technical textiles marketplace for high strength polymers.”

“What is exciting for the industry is the tremendous potential of these high strength fibers to satisfy the multi billion dollar demand for new materials with tremendous strength to weight ratios,” said Thompson. “The artificial DNA sequences are one of the keys to satisfying that demand.”

Kraig Biocraft Laboratories is a technology company focused on the development of commercially significant high-performance polymers and technical fiber. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including Spider Silk.

For more information on Kraig Biocraft Laboratories please visit the Company's web site: <http://www.KraigLabs.com>

An audio interview discussing corporate developments is also available on the website

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "efforts," "foresees," "future", "forecasts," "estimates", "intends," "develops," "researching," "research," "goal," "potential," "possibility," "pursue," "could", "should" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans,

intentions, marketing strategies, or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products and execute on its marketing plans may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

CONTACT: Kraig Biocraft Laboratories, Inc.
Kim Thompson, CEO
(517) 336-0807
info@KraigLabs.com